Trial Outcomes & Findings for Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma (NCT NCT04068831)

NCT ID: NCT04068831

Last Updated: 2024-12-27

Results Overview

confirmed complete response (iCR) or partial response (iPR) assessed by iRECIST.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

18 participants

Primary outcome timeframe

4 months

Results posted on

2024-12-27

Participant Flow

Participant milestones

Participant milestones
Measure
Talazoparib and Avelumab (VHL-deficiency) (Closed to Accrual)
All patients will receive combination treatment at the previously established recommended phase II dose, 800 mg avelumab every 2 weeks with 1 mg talazoparib daily, in 28-day cycles. Talazoparib: 1 mg talazoparib daily Avelumab: 800 mg avelumab every 2 weeks
Talazoparib and Avelumab (FH- or SDH-deficiency)
All patients will receive combination treatment at the previously established recommended phase II dose, 800 mg avelumab every 2 weeks with 1 mg talazoparib daily, in 28-day cycles. Talazoparib: 1 mg talazoparib daily Avelumab: 800 mg avelumab every 2 weeks
Overall Study
STARTED
10
8
Overall Study
COMPLETED
0
0
Overall Study
NOT COMPLETED
10
8

Reasons for withdrawal

Reasons for withdrawal
Measure
Talazoparib and Avelumab (VHL-deficiency) (Closed to Accrual)
All patients will receive combination treatment at the previously established recommended phase II dose, 800 mg avelumab every 2 weeks with 1 mg talazoparib daily, in 28-day cycles. Talazoparib: 1 mg talazoparib daily Avelumab: 800 mg avelumab every 2 weeks
Talazoparib and Avelumab (FH- or SDH-deficiency)
All patients will receive combination treatment at the previously established recommended phase II dose, 800 mg avelumab every 2 weeks with 1 mg talazoparib daily, in 28-day cycles. Talazoparib: 1 mg talazoparib daily Avelumab: 800 mg avelumab every 2 weeks
Overall Study
Disease Progression
10
8

Baseline Characteristics

Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Talazoparib and Avelumab (VHL-deficiency) (Closed to Accrual)
n=10 Participants
All patients will receive combination treatment at the previously established recommended phase II dose, 800 mg avelumab every 2 weeks with 1 mg talazoparib daily, in 28-day cycles. Talazoparib: 1 mg talazoparib daily Avelumab: 800 mg avelumab every 2 weeks
Talazoparib and Avelumab (FH- or SDH-deficiency)
n=8 Participants
All patients will receive combination treatment at the previously established recommended phase II dose, 800 mg avelumab every 2 weeks with 1 mg talazoparib daily, in 28-day cycles. Talazoparib: 1 mg talazoparib daily Avelumab: 800 mg avelumab every 2 weeks
Total
n=18 Participants
Total of all reporting groups
Age, Continuous
62 years
n=5 Participants
40 years
n=7 Participants
58 years
n=5 Participants
Sex: Female, Male
Female
8 Participants
n=5 Participants
6 Participants
n=7 Participants
14 Participants
n=5 Participants
Sex: Female, Male
Male
2 Participants
n=5 Participants
2 Participants
n=7 Participants
4 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
10 Participants
n=5 Participants
8 Participants
n=7 Participants
18 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
1 Participants
n=5 Participants
1 Participants
n=7 Participants
2 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=5 Participants
4 Participants
n=7 Participants
4 Participants
n=5 Participants
Race (NIH/OMB)
White
9 Participants
n=5 Participants
3 Participants
n=7 Participants
12 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Region of Enrollment
United States
10 Participants
n=5 Participants
8 Participants
n=7 Participants
18 Participants
n=5 Participants

PRIMARY outcome

Timeframe: 4 months

confirmed complete response (iCR) or partial response (iPR) assessed by iRECIST.

Outcome measures

Outcome measures
Measure
Talazoparib and Avelumab (VHL-deficiency) (Closed to Accrual)
n=10 Participants
All patients will receive combination treatment at the previously established recommended phase II dose, 800 mg avelumab every 2 weeks with 1 mg talazoparib daily, in 28-day cycles. Talazoparib: 1 mg talazoparib daily Avelumab: 800 mg avelumab every 2 weeks
Talazoparib and Avelumab (FH- or SDH-deficiency)
n=8 Participants
All patients will receive combination treatment at the previously established recommended phase II dose, 800 mg avelumab every 2 weeks with 1 mg talazoparib daily, in 28-day cycles. Talazoparib: 1 mg talazoparib daily Avelumab: 800 mg avelumab every 2 weeks
the Objective Response Rate (ORR)
Pts with ORR
0 Participants
0 Participants
the Objective Response Rate (ORR)
Pts without ORR
10 Participants
8 Participants

SECONDARY outcome

Timeframe: 2 years

by RECIST v1.1

Outcome measures

Outcome measures
Measure
Talazoparib and Avelumab (VHL-deficiency) (Closed to Accrual)
n=10 Participants
All patients will receive combination treatment at the previously established recommended phase II dose, 800 mg avelumab every 2 weeks with 1 mg talazoparib daily, in 28-day cycles. Talazoparib: 1 mg talazoparib daily Avelumab: 800 mg avelumab every 2 weeks
Talazoparib and Avelumab (FH- or SDH-deficiency)
n=8 Participants
All patients will receive combination treatment at the previously established recommended phase II dose, 800 mg avelumab every 2 weeks with 1 mg talazoparib daily, in 28-day cycles. Talazoparib: 1 mg talazoparib daily Avelumab: 800 mg avelumab every 2 weeks
Progression-free Survival (PFS)
3.5 months
Interval 1.0 to 3.9
1.2 months
Interval 0.4 to 2.9

Adverse Events

Talazoparib and Avelumab (VHL-deficiency) (Closed to Accrual)

Serious events: 3 serious events
Other events: 9 other events
Deaths: 9 deaths

Talazoparib and Avelumab (FH- or SDH-deficiency)

Serious events: 5 serious events
Other events: 8 other events
Deaths: 7 deaths

Serious adverse events

Serious adverse events
Measure
Talazoparib and Avelumab (VHL-deficiency) (Closed to Accrual)
n=10 participants at risk
All patients will receive combination treatment at the previously established recommended phase II dose, 800 mg avelumab every 2 weeks with 1 mg talazoparib daily, in 28-day cycles. Talazoparib: 1 mg talazoparib daily Avelumab: 800 mg avelumab every 2 weeks
Talazoparib and Avelumab (FH- or SDH-deficiency)
n=8 participants at risk
All patients will receive combination treatment at the previously established recommended phase II dose, 800 mg avelumab every 2 weeks with 1 mg talazoparib daily, in 28-day cycles. Talazoparib: 1 mg talazoparib daily Avelumab: 800 mg avelumab every 2 weeks
Cardiac disorders
Chest pain
10.0%
1/10 • 2 years
12.5%
1/8 • 2 years
Respiratory, thoracic and mediastinal disorders
Dyspnea
10.0%
1/10 • 2 years
37.5%
3/8 • 2 years
Nervous system disorders
Intracranial hemorrhage
10.0%
1/10 • 2 years
0.00%
0/8 • 2 years
Musculoskeletal and connective tissue disorders
Back pain
0.00%
0/10 • 2 years
12.5%
1/8 • 2 years
General disorders
Fatigue
0.00%
0/10 • 2 years
12.5%
1/8 • 2 years
Investigations
Platelet count decrease
0.00%
0/10 • 2 years
12.5%
1/8 • 2 years
Cardiac disorders
Cardiac arrest
0.00%
0/10 • 2 years
12.5%
1/8 • 2 years
General disorders
Chills
0.00%
0/10 • 2 years
12.5%
1/8 • 2 years
Injury, poisoning and procedural complications
Infusion related reaction
0.00%
0/10 • 2 years
12.5%
1/8 • 2 years
Respiratory, thoracic and mediastinal disorders
Respiratory failure
0.00%
0/10 • 2 years
12.5%
1/8 • 2 years
Respiratory, thoracic and mediastinal disorders
Hypoxia
0.00%
0/10 • 2 years
12.5%
1/8 • 2 years
Respiratory, thoracic and mediastinal disorders
Bronchopulmonary hemorrhage
10.0%
1/10 • 2 years
0.00%
0/8 • 2 years
Respiratory, thoracic and mediastinal disorders
Pleural effusion
10.0%
1/10 • 2 years
0.00%
0/8 • 2 years
Metabolism and nutrition disorders
Hyponatremia
0.00%
0/10 • 2 years
12.5%
1/8 • 2 years
Renal and urinary disorders
Acute Kidney Pain
0.00%
0/10 • 2 years
12.5%
1/8 • 2 years

Other adverse events

Other adverse events
Measure
Talazoparib and Avelumab (VHL-deficiency) (Closed to Accrual)
n=10 participants at risk
All patients will receive combination treatment at the previously established recommended phase II dose, 800 mg avelumab every 2 weeks with 1 mg talazoparib daily, in 28-day cycles. Talazoparib: 1 mg talazoparib daily Avelumab: 800 mg avelumab every 2 weeks
Talazoparib and Avelumab (FH- or SDH-deficiency)
n=8 participants at risk
All patients will receive combination treatment at the previously established recommended phase II dose, 800 mg avelumab every 2 weeks with 1 mg talazoparib daily, in 28-day cycles. Talazoparib: 1 mg talazoparib daily Avelumab: 800 mg avelumab every 2 weeks
General disorders
Fatigue
60.0%
6/10 • 2 years
75.0%
6/8 • 2 years
Blood and lymphatic system disorders
Anemia
30.0%
3/10 • 2 years
37.5%
3/8 • 2 years
Respiratory, thoracic and mediastinal disorders
Dyspnea
30.0%
3/10 • 2 years
37.5%
3/8 • 2 years
Gastrointestinal disorders
Nausea
30.0%
3/10 • 2 years
25.0%
2/8 • 2 years
Gastrointestinal disorders
Constipation
20.0%
2/10 • 2 years
37.5%
3/8 • 2 years
Respiratory, thoracic and mediastinal disorders
Cough
30.0%
3/10 • 2 years
25.0%
2/8 • 2 years
Nervous system disorders
Headache
20.0%
2/10 • 2 years
25.0%
2/8 • 2 years
Gastrointestinal disorders
Vomiting
10.0%
1/10 • 2 years
25.0%
2/8 • 2 years
Gastrointestinal disorders
Abdominal pain
20.0%
2/10 • 2 years
12.5%
1/8 • 2 years
Investigations
Creatinine increased
20.0%
2/10 • 2 years
12.5%
1/8 • 2 years
Gastrointestinal disorders
Diarrhea
20.0%
2/10 • 2 years
12.5%
1/8 • 2 years
Psychiatric disorders
Insomnia
20.0%
2/10 • 2 years
12.5%
1/8 • 2 years
Skin and subcutaneous tissue disorders
Rash maculo popular
20.0%
2/10 • 2 years
12.5%
1/8 • 2 years
Investigations
Platelet count decrease
10.0%
1/10 • 2 years
12.5%
1/8 • 2 years
Renal and urinary disorders
Acute kidney injury
0.00%
0/10 • 2 years
12.5%
1/8 • 2 years
Respiratory, thoracic and mediastinal disorders
Bronchopulmonary hemorrhage
10.0%
1/10 • 2 years
0.00%
0/8 • 2 years
Nervous system disorders
Intracranial hemorrhage
10.0%
1/10 • 2 years
0.00%
0/8 • 2 years
Cardiac disorders
Heart failure
10.0%
1/10 • 2 years
0.00%
0/8 • 2 years
Investigations
Neutrophil count decreased
10.0%
1/10 • 2 years
0.00%
0/8 • 2 years
Respiratory, thoracic and mediastinal disorders
Pleural effusion
10.0%
1/10 • 2 years
0.00%
0/8 • 2 years
Vascular disorders
Thromboembolic event
10.0%
1/10 • 2 years
0.00%
0/8 • 2 years

Additional Information

Dr. Ritesh Kotecha, MD

Memorial Sloan Kettering Cancer Center

Phone: 646-422-4791

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place